6849:TSENihon Kohden Corporation Analysis
Data as of 2026-03-16 - not real-time
¥1,486.50
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Nihon Kohden is trading at ¥1,486.5, barely above its technical support of ¥1,480.5, suggesting limited downside cushion. The 14‑day RSI sits at 31, placing the stock in oversold territory and hinting at a possible short‑term bounce. However, the MACD remains bearish, with the histogram below zero, indicating that downward momentum still dominates. Valuation metrics are compelling: the trailing PE of 13.5 is less than half the industry average of 26.2, and the price‑to‑book of 1.4 aligns with its book value. The DCF‑derived fair value of roughly ¥1,992 implies an upside of over 40% from current levels. Meanwhile, the company yields 2.12% on dividends with a modest payout ratio of 29%, supported by strong operating cash flow and a healthy free cash flow balance sheet.
Fundamentally, revenue growth is flat at 0.4% and margins are thin (operating margin 4.3%), but the firm maintains a solid cash position of ¥44 bn against ¥25 bn of debt. Its beta of around 0.24 (market data) and a computed beta under 0.5 point to low systematic risk, while 30‑day volatility of 38% signals price swings that can be exploited. The recent analyst consensus of “Buy” from seven analysts, with a median target near ¥1,980, reinforces the upside narrative. The dividend policy appears sustainable given the strong free cash flow and low payout. Geographic exposure across Japan, North America, Europe and Asia diversifies revenue streams, mitigating single‑region shocks. Overall, the combination of undervaluation, attractive yield, and defensive risk profile makes the stock a compelling candidate for medium‑ to long‑term accumulation.
Fundamentally, revenue growth is flat at 0.4% and margins are thin (operating margin 4.3%), but the firm maintains a solid cash position of ¥44 bn against ¥25 bn of debt. Its beta of around 0.24 (market data) and a computed beta under 0.5 point to low systematic risk, while 30‑day volatility of 38% signals price swings that can be exploited. The recent analyst consensus of “Buy” from seven analysts, with a median target near ¥1,980, reinforces the upside narrative. The dividend policy appears sustainable given the strong free cash flow and low payout. Geographic exposure across Japan, North America, Europe and Asia diversifies revenue streams, mitigating single‑region shocks. Overall, the combination of undervaluation, attractive yield, and defensive risk profile makes the stock a compelling candidate for medium‑ to long‑term accumulation.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- price at technical support level
- RSI indicating oversold condition
- MACD still showing bearish momentum
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- DCF fair value suggests >40% upside
- attractive dividend yield with low payout ratio
- PE well below industry average
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- strong cash generation and balance sheet
- sustained demand for medical device solutions
- low systematic risk and diversified geographic exposure
Key Metrics & Analysis
Financial Health
Revenue Growth0.40%
Profit Margin5.36%
P/E Ratio13.5
ROE7.09%
ROA4.80%
Debt/Equity14.81
P/B Ratio1.4
Op. Cash Flow¥21.5B
Free Cash Flow¥22.1B
Industry P/E26.2
Technical Analysis
TrendNeutral
RSI31.5
Support¥1,480.50
Resistance¥1,740.00
MA 20¥1,616.63
MA 50¥1,696.82
MA 200¥1,686.04
MACDBearish
VolumeStable
Fear & Greed Index72.88
Valuation
Fair Value¥1,992.21
Target Price¥2,104.29
Upside/Downside41.56%
GradeUndervalued
TypeBlend
Dividend Yield2.12%
Risk Assessment
Beta0.48
Volatility38.34%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.